HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Stranded asset discovery

Find leads where development or the surrounding company stopped. Discovery priority is separate from buyer qualification.

Bounded historical coverage · 0 HIGH / 111 MEDIUM / 956 LOW. No current availability or investment recommendation is implied. SEC retrieval is partial.

1067 exact-label leads · page 17

LOW · POSSIBLE / INVESTIGATE

Asenapine

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · New label

LOW · POSSIBLE / INVESTIGATE

Aspirin

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · POSSIBLE / INVESTIGATE

Aspirin 325mg

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · POSSIBLE / INVESTIGATE

Atazanavir

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · POSSIBLE / INVESTIGATE

Atezolizumab

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · UNKNOWN

Autologous Human Cord Blood derived Stem Cell injection

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · UNKNOWN confidence · New label

LOW · UNKNOWN

Autologous Human Umbilical Cord Blood

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · UNKNOWN confidence · New label

LOW · POSSIBLE / INVESTIGATE

Autologous total tumor mRNA loaded DOTAP liposome vaccine

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · POSSIBLE / INVESTIGATE

Avelumab

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · POSSIBLE / INVESTIGATE

Axatilimab

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap

LOW · UNKNOWN

Axitinib Plus Pembrolizumab or Toripalimab

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · UNKNOWN confidence · New label

LOW · POSSIBLE / INVESTIGATE

Azacitidine

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN · Trial reasons are not asset-level verdicts.

Buyer qualification: UNKNOWN · Control: UNKNOWN

MODEL INFERENCE · LOW confidence · Prior label overlap